BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. Cancer 2017;123:751-8. [PMID: 27911488 DOI: 10.1002/cncr.30462] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Chan LKL, Mak VWM, Chan SCH, Yu ELM, Chan NCN, Leung KFS, Ng CKM, Ng MHL, Chan JCW, Lee HKK. Liver complications of haemoglobin H disease in adults. Br J Haematol 2021;192:171-8. [PMID: 33095929 DOI: 10.1111/bjh.17115] [Reference Citation Analysis]
2 Yang T, Du G, Cui Y, Yu R, Hua C, Tian W, Zhang Y. pH-sensitive doxorubicin-loaded polymeric nanocomplex based on β-cyclodextrin for liver cancer-targeted therapy. Int J Nanomedicine 2019;14:1997-2010. [PMID: 30962684 DOI: 10.2147/IJN.S193170] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Troadec M, Loréal O, Brissot P. The interaction of iron and the genome: For better and for worse. Mutation Research/Reviews in Mutation Research 2017;774:25-32. [DOI: 10.1016/j.mrrev.2017.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
4 Marsella M, Ricchi P. Thalassemia and hepatocellular carcinoma: links and risks. J Blood Med 2019;10:323-34. [PMID: 31572038 DOI: 10.2147/JBM.S186362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
5 Amin S, Jalal S, Ali K, Rasool L, Osman T, Ali O, M-Saeed A. Molecular Characterization and Disease-Related Morbidities of β-Thalassemia Patients from the Northeastern Part of Iraq. Int J Gen Med 2020;13:1453-67. [PMID: 33335418 DOI: 10.2147/IJGM.S277947] [Reference Citation Analysis]
6 Ponti ML, Comitini F, Murgia D, Ganga R, Canu R, Dessì C, Foschini ML, Leoni G, Morittu M, Perra M, Pilia MP, Casini MR, Zappu A, Origa R. Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major. Dig Liver Dis 2019;51:561-7. [PMID: 30658940 DOI: 10.1016/j.dld.2018.12.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Bou-Fakhredin R, Bazarbachi AH, Chaya B, Sleiman J, Cappellini MD, Taher AT. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia. Int J Mol Sci 2017;18:E2778. [PMID: 29261151 DOI: 10.3390/ijms18122778] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Taher AT, Cappellini MD. How I manage medical complications of β-thalassemia in adults. Blood 2018;132:1781-91. [PMID: 30206117 DOI: 10.1182/blood-2018-06-818187] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
9 Aliyeva G, Asadov C, Mammadova T, Gafarova S, Abdulalimov E. Thalassemia in the laboratory: pearls, pitfalls, and promises. Clinical Chemistry and Laboratory Medicine (CCLM) 2018;57:165-74. [DOI: 10.1515/cclm-2018-0647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
10 Wang Z, Duan X, Lv Y, Zhao Y. Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers. Life Sci 2019;239:117013. [PMID: 31678287 DOI: 10.1016/j.lfs.2019.117013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
11 Finianos A, Matar CF, Taher A. Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. Int J Mol Sci 2018;19:E4070. [PMID: 30562917 DOI: 10.3390/ijms19124070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
12 Maffei L, Sorrentino F, Caprari P, Taliani G, Massimi S, Risoluti R, Materazzi S. HCV Infection in Thalassemia Syndromes and Hemoglobinopathies: New Perspectives. Front Mol Biosci 2020;7:7. [PMID: 32118034 DOI: 10.3389/fmolb.2020.00007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Li M, Chen J, Yu X, Xu S, Li D, Zheng Q, Yin Y. Myricetin Suppresses the Propagation of Hepatocellular Carcinoma via Down-Regulating Expression of YAP. Cells 2019;8:E358. [PMID: 30999669 DOI: 10.3390/cells8040358] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
14 Bhuyan GS, Noor AUZ, Sultana R, Noor FA, Sultana N, Sarker SK, Islam MT, Sayeed MA, Khabir MIU, Hossain AKME, Zeba Z, Qadri SK, Siddique MRF, Qadri SS, Qadri F, Mannoor K. Frequency of Hepatitis B, C and HIV Infections among Transfusion-Dependent Beta Thalassemia Patients in Dhaka. Infect Dis Rep 2021;13:89-95. [PMID: 33467675 DOI: 10.3390/idr13010011] [Reference Citation Analysis]
15 Faham S, Golmohammadi H, Ghavami R, Khayatian G. A nanocellulose-based colorimetric assay kit for smartphone sensing of iron and iron-chelating deferoxamine drug in biofluids. Analytica Chimica Acta 2019;1087:104-12. [DOI: 10.1016/j.aca.2019.08.056] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
16 Moukhadder HM, Roumi JE, Bou-Fakhredin R, Taher AT. Hepatocellular Carcinoma in a β-Thalassemia Intermedia Patient: Yet Another Case in the Expanding Epidemic. Hemoglobin 2018;42:58-60. [PMID: 29493312 DOI: 10.1080/03630269.2018.1434197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 Casu C, Chessa R, Liu A, Gupta R, Drakesmith H, Fleming R, Ginzburg YZ, MacDonald B, Rivella S. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major. Haematologica 2020;105:1835-44. [PMID: 31582543 DOI: 10.3324/haematol.2018.212589] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
18 Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. Int J Mol Sci 2018;19:E182. [PMID: 29316681 DOI: 10.3390/ijms19010182] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
19 Telek E, Ujfalusi Z, Kemenesi G, Zana B, Jakab F, Hild G, Lukács A, Hild G. A Possible Way to Relate the Effects of SARS-CoV-2-Induced Changes in Transferrin to Severe COVID-19-Associated Diseases. IJMS 2022;23:6189. [DOI: 10.3390/ijms23116189] [Reference Citation Analysis]
20 Marcon A, Motta I, Taher AT, Cappellini MD. Clinical Complications and Their Management. Hematology/Oncology Clinics of North America 2018;32:223-36. [DOI: 10.1016/j.hoc.2017.11.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
21 Shah FT, Porter JB, Sadasivam N, Kaya B, Moon JC, Velangi M, Ako E, Pancham S. Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. Br J Haematol 2021. [PMID: 34617272 DOI: 10.1111/bjh.17839] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD. Management of age-associated medical complications in patients with β-thalassemia. Expert Review of Hematology 2020;13:85-94. [DOI: 10.1080/17474086.2020.1686354] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
23 Eziefula C, Shah FT, Anie KA. Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients. PPA 2022;Volume 16:1423-37. [DOI: 10.2147/ppa.s269352] [Reference Citation Analysis]
24 Farmakis D, Giakoumis A, Angastiniotis M, Eleftheriou A. The changing epidemiology of the ageing thalassaemia populations: A position statement of the Thalassaemia International Federation. Eur J Haematol 2020;105:16-23. [PMID: 32198891 DOI: 10.1111/ejh.13410] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
25 Hodroj MH, Bou-fakhredin R, Nour-eldine W, Noureldine HA, Noureldine MHA, Taher AT. Thalassemia and malignancy: An emerging concern? Blood Reviews 2019;37:100585. [DOI: 10.1016/j.blre.2019.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
26 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
27 Feng X, Hu W, Hong Y, Ruan L, Hu Y, Liu D, Jia Z. Taurine Ameliorates Iron Overload-Induced Hepatocyte Injury via the Bcl-2/VDAC1-Mediated Mitochondrial Apoptosis Pathway. Oxidative Medicine and Cellular Longevity 2022;2022:1-14. [DOI: 10.1155/2022/4135752] [Reference Citation Analysis]
28 Asadov C, Alimirzoeva Z, Mammadova T, Aliyeva G, Gafarova S, Mammadov J. β-Thalassemia intermedia: a comprehensive overview and novel approaches. Int J Hematol 2018;108:5-21. [PMID: 29380178 DOI: 10.1007/s12185-018-2411-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
29 Kang FB, Wang L, Sun DX, Li HJ, Li D, Wang Y, Kang JW. B7-H4 overexpression is essential for early hepatocellular carcinoma progression and recurrence. Oncotarget 2017;8:80878-88. [PMID: 29113351 DOI: 10.18632/oncotarget.20718] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
30 Ben Salah N, Bou-Fakhredin R, Mellouli F, Taher AT. Revisiting beta thalassemia intermedia: past, present, and future prospects. Hematology 2017;22:607-16. [PMID: 28589785 DOI: 10.1080/10245332.2017.1333246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
31 Papadopoulos N, Kountouras D, Malagari K, Tampaki M, Theochari M, Koskinas J. Characteristics and Prognosis of Hepatocellular Carcinoma in Multi-Transfused Patients with β-Thalassemia. Experience of a Single Tertiary Center. Mediterr J Hematol Infect Dis 2020;12:e2020013. [PMID: 32180908 DOI: 10.4084/MJHID.2020.013] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Hsu CC, Senussi NH, Fertrin KY, Kowdley KV. Iron overload disorders. Hepatol Commun 2022. [PMID: 35699322 DOI: 10.1002/hep4.2012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chapin J, Cohen AR, Neufeld EJ, Vichinsky E, Giardina PJ, Boudreaux J, Le BC, Kenney K, Trimble S, Thompson AA. An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres. Br J Haematol 2021. [PMID: 34775608 DOI: 10.1111/bjh.17920] [Reference Citation Analysis]
34 Wang W, Li Q, Huang G, Lin BY, Lin D, Ma Y, Zhang Z, Chen T, Zhou J. Tandem Mass Tag-Based Proteomic Analysis of Potential Biomarkers for Hepatocellular Carcinoma Differentiation. Onco Targets Ther 2021;14:1007-20. [PMID: 33603407 DOI: 10.2147/OTT.S273823] [Reference Citation Analysis]
35 Mancuso A. Evidence-based medicine and Management of Hepatocellular Carcinoma in Thalassemia. BMC Gastroenterol 2020;20:409. [PMID: 33297979 DOI: 10.1186/s12876-020-01542-2] [Reference Citation Analysis]
36 Sousa L, Oliveira MM, Pessôa MTC, Barbosa LA. Iron overload: Effects on cellular biochemistry. Clin Chim Acta 2020;504:180-9. [PMID: 31790701 DOI: 10.1016/j.cca.2019.11.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
37 d'Assignies G, Paisant A, Bardou-Jacquet E, Boulic A, Bannier E, Lainé F, Ropert M, Morcet J, Saint-Jalmes H, Gandon Y. Non-invasive measurement of liver iron concentration using 3-Tesla magnetic resonance imaging: validation against biopsy. Eur Radiol 2018;28:2022-30. [PMID: 29178028 DOI: 10.1007/s00330-017-5106-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
38 Zheng C, Liu X, Chen L, Xu Z, Shao J. lncRNAs as prognostic molecular biomarkers in hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:59638-47. [PMID: 28938667 DOI: 10.18632/oncotarget.19559] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]